PMID- 19845952
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20091214
LR  - 20211020
IS  - 1742-6405 (Electronic)
IS  - 1742-6405 (Linking)
VI  - 6
DP  - 2009 Oct 21
TI  - HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai 
      patients.
PG  - 22
LID - 10.1186/1742-6405-6-22 [doi]
AB  - BACKGROUND: A high incidence of rash has been reported in HIV-1 patients who 
      received the anti-retroviral drug nevirapine. In addition, several studies have 
      suggested that polymorphisms of human leukocyte antigen (HLA) genes may play 
      important roles in nevirapine-induced rash. The aim of the present study was to 
      evaluate the effects of different HLA-C alleles on rash associated with 
      nevirapine in patients who started highly active anti-retroviral therapy (HAART) 
      containing nevirapine in Thailand. RESULTS: A case-control study was carried out 
      involving HIV-1 patients under treatment at Bamrasnaradura Infectious Diseases 
      Institute, Nonthaburi, Thailand between March 2007 and March 2008. The study 
      included all HIV/AIDS patients being treated with nevirapine-containing regimens. 
      The study population comprised 287 HIV/AIDS patients of whom 248 were 
      nevirapine-tolerant and 39 developed rash after nevirapine treatment. From the 
      nevirapine-tolerant patients, 60 were selected as the control group on the basis 
      of age, sex, and therapy history matched for nevirapine-induced rash cases. We 
      observed significantly more HLA-Cw*04 alleles in nevirapine-induced rash cases 
      than in nevirapine-tolerant group, with frequencies of 20.51% and 7.50%, 
      respectively (P = 0.009). There were no significant differences between the rash 
      and tolerant groups for other HLA-C alleles except for HLA-Cw*03 (P = 0.015). 
      CONCLUSION: This study suggests that HLA-Cw*04 is associated with rash in 
      nevirapine treated Thais. Future screening of patients' HLA may reduce the number 
      of nevirapine-induced rash cases, and patients with alleles associated with 
      nevirapine-induced rash should be started on anti-retroviral therapy without 
      nevirapine.
FAU - Likanonsakul, Sirirat
AU  - Likanonsakul S
AD  - Bamrasnaradura Infectious Diseases Institute, Department of Disease Control, 
      Ministry of Public Health, Nonthaburi, Thailand. imvbi@health2.moph.go.th
FAU - Rattanatham, Tippawan
AU  - Rattanatham T
FAU - Feangvad, Siriluk
AU  - Feangvad S
FAU - Uttayamakul, Sumonmal
AU  - Uttayamakul S
FAU - Prasithsirikul, Wisit
AU  - Prasithsirikul W
FAU - Tunthanathip, Preecha
AU  - Tunthanathip P
FAU - Nakayama, Emi E
AU  - Nakayama EE
FAU - Shioda, Tatsuo
AU  - Shioda T
LA  - eng
PT  - Journal Article
DEP - 20091021
PL  - England
TA  - AIDS Res Ther
JT  - AIDS research and therapy
JID - 101237921
PMC - PMC2774340
EDAT- 2009/10/23 06:00
MHDA- 2009/10/23 06:01
PMCR- 2009/10/21
CRDT- 2009/10/23 06:00
PHST- 2009/08/19 00:00 [received]
PHST- 2009/10/21 00:00 [accepted]
PHST- 2009/10/23 06:00 [entrez]
PHST- 2009/10/23 06:00 [pubmed]
PHST- 2009/10/23 06:01 [medline]
PHST- 2009/10/21 00:00 [pmc-release]
AID - 1742-6405-6-22 [pii]
AID - 10.1186/1742-6405-6-22 [doi]
PST - epublish
SO  - AIDS Res Ther. 2009 Oct 21;6:22. doi: 10.1186/1742-6405-6-22.